恒瑞医药：收到瑞维鲁胺片临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of its drug, Ruvelimab tablets, in combination with HS-20093 for prostate cancer treatment [2] Group 1: Company Developments - Heng Rui Medicine announced the approval of clinical trials for Ruvelimab tablets, a second-generation AR inhibitor, which has a stronger AR inhibition effect compared to first-generation AR inhibitors and does not have agonistic effects [2] - Ruvelimab tablets were approved for market launch in 2022 for the treatment of high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [2] Group 2: Industry Context - The market currently has several second-generation AR inhibitors available, including Enzalutamide, Apalutamide, and Darolutamide [2]